U.S. markets open in 21 minutes
  • S&P Futures

    4,094.00
    +12.75 (+0.31%)
     
  • Dow Futures

    34,634.00
    +35.00 (+0.10%)
     
  • Nasdaq Futures

    12,074.00
    +31.75 (+0.26%)
     
  • Russell 2000 Futures

    1,893.80
    +6.30 (+0.33%)
     
  • Crude Oil

    82.19
    +1.64 (+2.04%)
     
  • Gold

    1,803.40
    +43.50 (+2.47%)
     
  • Silver

    22.43
    +0.65 (+2.98%)
     
  • EUR/USD

    1.0503
    +0.0095 (+0.91%)
     
  • 10-Yr Bond

    3.5850
    -0.1180 (-3.19%)
     
  • Vix

    20.59
    -1.30 (-5.94%)
     
  • GBP/USD

    1.2237
    +0.0175 (+1.45%)
     
  • USD/JPY

    136.1220
    -1.9580 (-1.42%)
     
  • BTC-USD

    17,069.67
    +242.10 (+1.44%)
     
  • CMC Crypto 200

    404.16
    +3.46 (+0.86%)
     
  • FTSE 100

    7,574.87
    +1.82 (+0.02%)
     
  • Nikkei 225

    28,226.08
    +257.09 (+0.92%)
     

Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings

  • Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609.

  • Updated data demonstrated clinical activity in heavily pre-treated patients across multiple tumor settings.

  • The data were presented at the European Society for Medical Oncology Congress (ESMO21) 2021.

  • Thirteen patients (28.9%) achieved stable disease (SD), with six patients' tumor regressions of up to 20% across multiple tumor types.

  • The most substantial clinical activity was observed in heavily pre-treated patients with advanced pancreatic cancer.

  • Five of 13 (38.5%) evaluable patients achieved SD, with tumor reductions in two patients.

  • Reductions in the CA 19-9 tumor marker were observed in three of four pancreatic cancer patients. These reductions ranged from 32% to 72%.

  • One metastatic pancreatic cancer patient who had failed two prior lines of therapy and relapsed after the third line of treatment, experienced prolonged SD of up to 10 months.

  • Syros plans to initiate an expansion cohort evaluating SY-5609 in combination with chemotherapy for pancreatic cancer in Q4 of 2021.

  • The Company also plans to initiate a Phase 1b trial evaluating SY-5609 in combination with Bruton's tyrosine kinase (BTK) inhibitor for mantle cell lymphoma in 1H of 2022 the first half of 2022.

  • Price Action: SYRS stock is down 2.36% at $4.96 during the market session on the last check Monday.

  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.